A class of ketoamide derivatives and pharmaceutical uses thereof are provided. Specifically provided are the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or a deuterated compound thereof. The compound can effectively inhibit the activity of SARS-CoV-2 Mpro, and can be used in the manufacturer of SARS-CoV-2 Mpro inhibitors, blocking the replication and transcription of SARS-CoV-2 virus in patients. The compound can be used in preparing SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 medicaments, as well as the medicaments for preventing and/or treating Corona Virus Disease 2019 (COVID-19).
A class of ketoamide derivatives and pharmaceutical uses thereof are provided. Specifically provided are the compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or a deuterated compound thereof. The compound can effectively inhibit the activity of SARS-CoV-2 Mpro, and can be used in the manufacturer of SARS-CoV-2 Mpro inhibitors, blocking the replication and transcription of SARS-CoV-2 virus in patients. The compound can be used in preparing SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 medicaments, as well as the medicaments for preventing and/or treating Corona Virus Disease 2019 (COVID-19).
C07D 239/26 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant au moins trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 241/12 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
2.
PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB
The present invention relates to the field of medicine, and in particular to a protein, adenovirus and vaccine against infection of a subtype of SARS-CoV-2 Omicron mutant strain XBB. In order to solve the problem of lack of effective prevention and treatment drugs against infection of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, the present invention provides a protein, adenovirus and vaccine against the infection of the subtype of the SARS-CoV-2 Omicron mutant strain XBB. The vaccine is designed by optimizing the sequences of full-length S proteins of sub-lines XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2 of the SARS-CoV-2 Omicron mutant strain XBB, and RBD and RBD-HR sequences in the S proteins, can help a host to resist coronavirus infection, and in particular has a good prevention and treatment effect on cross infection caused by subtype viruses of the Omicron mutant strain XBB.
The present invention belongs to the field of biomedicine, and particularly relates to an industrial production method for a Staphylococcus aureus vaccine. The method provided by the present invention ensures industrial production of a vaccine comprising multiple immunogenic components such as whole-cell Staphylococcus aureus with stable and controllable quality. The vaccine prepared by the present invention has good immunogenicity, not only an actual inoculated dose is low, but also the vaccine can prevent multiple infectious diseases caused by drug-resistant Staphylococcus aureus.
Provided is a vaccine against respiratory syncytial virus infection. In view of the lack of effective prevention and treatment drugs for respiratory syncytial virus infection for the elderly, infants, and people with low immunity, a vaccine against respiratory syncytial virus infection is provided. The vaccine is based on adenovirus as a vector, and the antigen gene expressed is optimized based on the sequence of respiratory syncytial virus F protein. The adenovirus vector vaccine can help a host resist respiratory syncytial virus infection and has a good preventive and therapeutic effect.
C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
5.
ANTI-ACNE RECOMBINANT PROTEIN VACCINE, PREPARATION METHOD, AND USE
Provided are an anti-acne recombinant protein vaccine, a preparation method, and a use. In order to solve the current problem that there is still a lack of a drug for effective prevention and treatment for acne diseases, a recombinant protein vaccine targeting a CAMP virulence factor of Cutibacterium acnes is provided, which is mainly used for inducing an immune response in vivo, such as the production of antibodies, to neutralize the CAMP virulence factor and inhibit Cutibacterium acnes-induced skin inflammation, so as to have the effect of preventing and treating acne.
Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
A61P 31/14 - Antiviraux pour le traitement des virus ARN
The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.
The invention pertains to the technical fields of genetic engineering and cell engineering, and in particular relates to a rhabdovirus-negative Spodoptera frugiperda insect cell line, and screening, identification and application thereof. According to the invention, the rhabdovirus-negative Spodoptera frugiperda insect cell line WSK-Sf9, with a CCTCC accession number C202246, is obtained through screening and identification. The cell line is verified through various high-sensitivity test methods such as nested PCR, transcriptome next-generation sequencing, real-time fluorescence quantitative PCR and TAQMAN probe-based real-time PCR, and finally obtained the Sf-rhabdovirus-negative Spodoptera frugiperda insect cell line WSK-Sf9. The cell is tested for sterility, mycoplasma, exogenous virus and tumorigenicity according to pharmacopeial requirements, and the results show that all indicators satisfy the requirements, and the cell can be used in or for the production of recombinant proteins and recombinant protein vaccines based on the baculovirus expression system.
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevention and treatment drugs against infections of the SARS-CoV-2 Omicron mutant strain XBB and the subtype thereof, the protein and the vaccine against the infections of SARS-CoV-2 Omicron mutant strain XBB and the subtype thereof are provided. The vaccine is designed on the basis of the full-length S protein of SARS-CoV-2 Omicron mutant strain XBB and sub-line XBB, the RBD sequence in the S protein, and an optimized sequence thereof. The vaccine can assist the host in resisting coronavirus infection, and in particular has a relatively good prevention and treatment effect with regard to cross infections caused by the SARS-CoV-2 Omicron mutant strain XBB and a subtype virus thereof.
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
The present invention belongs to the technical field of genetic engineering and cell engineering, and particularly relates to a rhabdovirus negative Spodoptera frugiperda insect cell strain, screening therefor, identification thereof and use thereof. According to the present invention, a rhabdovirus negative Spodoptera frugiperda insect cell strain WSK-Sf9 is obtained by means of screening and identification and is deposited under CCTCC NO: C202246. The cell strain is verified by means of a variety of different high-sensitivity assay methods, such as nested PCR, transcriptome next-generation sequencing, fluorescence-based quantitative PCR and probe-based quantitative PCR, and the Sf-rhabdovirus negative Spodoptera frugiperda insect cell strain WSK-Sf9 is finally obtained by means of screening. The cell is tested for asepsis, mycoplasma, exogenous viruses, tumorigenicity, etc. according to pharmacopoeial requirements, and the results show that the cell meets the requirements in all the tests; the cell can produce recombinant proteins on the basis of a baculovirus expression system and can be used for recombinant protein vaccine production.
The present invention provides keto amide derivatives and the pharmaceutical use thereof, belonging to the technical field of organic synthesis drugs. Specifically provided are a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an enantiomer thereof, or a deuterated compound thereof. The compound may effectively inhibit SARS-CoV-2 Mproactivity, may be used for preparing an SARS-CoV-2 Mproinhibitor, and blocks replication and transcription of SARS-CoV-2 virus in a patient. The compound of the present invention has a very good use prospect in the preparation of SARS-CoV-2 Mpro inhibitors, anti-SARS-CoV-2 drugs, and drugs for preventing and/or treating COVID-19.
C07D 239/26 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant au moins trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 241/12 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 277/28 - Radicaux substitués par des atomes d'azote
C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 233/64 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle, p. ex. histidine
The present invention belongs to the technical field of genetic engineering and cell engineering, and particularly relates to a rhabdovirus negative Spodoptera frugiperda insect cell strain, screening therefor, identification thereof and use thereof. According to the present invention, a rhabdovirus negative Spodoptera frugiperda insect cell strain WSK-Sf9 is obtained by means of screening and identification and is deposited under CCTCC NO: C202246. The cell strain is verified by means of a variety of different high-sensitivity assay methods, such as nested PCR, transcriptome next-generation sequencing, fluorescence-based quantitative PCR and probe-based quantitative PCR, and the Sf-rhabdovirus negative Spodoptera frugiperda insect cell strain WSK-Sf9 is finally obtained by means of screening. The cell is tested for asepsis, mycoplasma, exogenous viruses, tumorigenicity, etc. according to pharmacopoeial requirements, and the results show that the cell meets the requirements in all the tests; the cell can produce recombinant proteins on the basis of a baculovirus expression system and can be used for recombinant protein vaccine production.
A method for the industrial production of a vaccine against Pseudomonas aeruginosa. By using a series of standardized, programmed and digital settings, it is ensured that a vaccine with stable quality containing whole Pseudomonas aeruginosa and multiple immunogenic components in Pseudomonas aeruginosa is produced. The obtained vaccine has good immunogenicity, can prevent infectious diseases caused by multiple types of Pseudomonas aeruginosa, and also has weak side effects and high safety.
The present invention relates to the anti-SARS-CoV-2-infection protein and vaccine, and belongs to the field of medicine. Due to the lack of efficient drugs for SARS-CoV-2 infection prevention and treatment in the prior art, the present invention provides an anti-SARS-CoV-2-infection protein, which contains a domain that binds with the angiotensin-converting enzyme 2 (ACE2) receptor as contained in the SARS-CoV-2 S protein. One the other hand, the present invention also provides a vaccine for SARS-CoV-2 infection prevention and/or treatment, which comprises the anti-SARS-CoV-2-infection protein as well as the pharmaceutically acceptable excipient or auxiliary ingredient. The present invention mainly induces the production of antibodies in the body for immunoreaction and blocks the binding the SARS-CoV-2 S protein and the ACE2 receptor of the host cell, thus helping the host to fight against the corona virus infection.
The present invention belongs to the field of biomedicine, and particularly relates to an industrial production method for a staphylococcus aureus vaccine.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemico-pharmaceutical preparations; Vaccines; Preparations of microorganisms for medical or veterinary use; injectable pharmaceuticals; Biochemical medicine; Medicines for human purposes; Pharmaceutical preparations; Antiseptics; Chemical reagents for medical or veterinary purposes; Antibiotics.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemico-pharmaceutical preparations; Vaccines; Preparations of microorganisms for medical or veterinary use; injectable pharmaceuticals; Biochemical medicine; Medicines for human purposes; Pharmaceutical preparations; Antiseptics; Chemical reagents for medical or veterinary purposes; Antibiotics.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemico-pharmaceutical preparations; Vaccines; Preparations of microorganisms for medical or veterinary use; injectable pharmaceuticals; Biochemical medicine; Medicines for human purposes; Pharmaceutical preparations; Antiseptics; Chemical reagents for medical or veterinary purposes; Antibiotics.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemico-pharmaceutical preparations; vaccines; preparations of microorganisms for medical or veterinary use; medicines for human purposes; antiseptics; chemical reagents for medical or veterinary purposes; antibiotics; injection medicines; Pharmaceutical preparations; Biochemical preparations for medical use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemico-pharmaceutical preparations; vaccines; preparations of microorganisms for medical or veterinary use; medicines for human purposes; antiseptics; chemical reagents for medical or veterinary purposes; antibiotics; injection medicines; Pharmaceutical preparations; Biochemical preparations for medical use.
The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
